Almac is proud to support multiple programs to accelerate COVID-19 treatment

 
Home /

Almac is proud to support over 140 separate crucial research programs to accelerate COVID-19 treatment

We are proud that Almac is continuing to play our part in the fight against the COVID-19 pandemic.

We are continuing to partner with a variety of global pharmaceutical, biotech and research institutions to support over 140 separate crucial research projects into COVID-19 treatment options.  In addition, we are currently in discussions with clients on how we can support an additional 60 programmes.

We are supporting this urgent research need through a range of service areas, including analytical services, peptide development, expedited Interactive Response Technology (IRT) support and clinical trial manufacturing, packaging and distribution.

These vital projects cover a range of different areas including vaccines and various potential treatments for symptoms and the effects of this disease.

In addition to this immediate research support, Almac continues to directly contribute to key operations in the supply chain of hundreds of life-saving drugs in a wide variety of therapeutic areas including oncology, neurology, pain management and cardiovascular.

Almac continues to conduct critical business operations and our dedicated, skilled employees will continue to support these critical supply chains.

To find out more about how Almac can support your project please contact us and we will be happy to discuss your specific requirements.

Latest news and resources

Supporting multiple programs through a range of service areas

Accelerating study start up with Simplify™ IRT

Leveraging the power of the industry’s leading IRT offering flexibility without delay, the Almac Simplify team devoted themselves day and night to get a system up and running, and ready to randomise the first patient in just six days.

Learn more
<h3 data-src=
This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies